clinical trial · NCT06335355
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Shanghai Shengdi Pharmaceutical Co., Ltd·phase3·not yet recruiting·n = 401
Non-squamous Non-small Cell Lung CancerAdebrelimab + SHR-8068 + Pemetrexed + CarboplatinCamrelizumab + Pemetrexed + CarboplatinAdebrelimab + Pemetrexed + Carboplatin
brief summary
Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations
started
Mar 1, 2024
primary completion
Oct 1, 2028
completion
Oct 1, 2030
last updated
Mar 28, 2024
official title
A Phase II/III, Randomized, Open-label, Parallel-controlled, Multicenter Study of Adebrelimab (SHR-1316) in Combination With SHR-8068 and Platinum-based Doublet Chemotherapy as First-line Treatment in Advanced or Metastatic NSCLC Patients With STK11/KEAP1/KRAS Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol